Recent Updates
Recently added Catalysts

Octreotide Long Acting Release

Phase 3

Chemotherapy-induced Diarrhea | Small molecule | Gastrointestinal |Novartis AG|Last Updated: May 4, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment139
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00582426Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced DiarrheaPHASE3 COMPLETED 139Apr 1, 2008Sep 1, 2010May 4, 201511 Brazil
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Participants Developing Diarrhea (Grade 1 to 4)
6 month overall

The percentage of patients developing diarrhea (incidence of grade 1 to 4) during treatment, considering only the worst grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0=None, 1 = Increase of \<4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse.

Secondary Endpoints
Number of Episodes of Diarrhea by Patient
6 months overall
Number of Episodes of Diarrhea by Patient by Cycle
at each cycle (28 days per cycle)
Percentage of Patients by Grade of Diarrhea
6 months overall
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Octreotide Long Acting ReleaseEXPERIMENTALPrevention of Chemotherapy Induced Diarrhea (CID)
Standard TreatmentOTHERPhysician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
Interventions
NameTypeDescription
Octreotide Long Acting ReleaseDRUGPatients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.
Standard TreatmentOTHERPhysician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 80 Years
SexALL
Healthy VolunteersNo
Study Sites11

Inclusion criteria: 1. Providing a written informed consent 2. Age between 18 and 80 years; 3. Histological diagnosis of colorectal cancer, presence of metastatic disease and no prior systemic therapy for metastatic disease (prior adjuvant therapy will be allowed if completed 6 months or longer bef...

Countries:Brazil
Unlock Eligibility Criteria